Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint

/PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Related Keywords

China ,Taiwan ,Japan ,United States ,Hong Kong ,Macau ,Suzhou ,Jiangsu ,Chinese ,Innovent Biologics ,Adimab Incyte ,Eli Lilly ,Wenying Yang ,Clinical Development Of Innovent ,Company Lilly ,Prnewswire Innovent Biologics Inc ,Md Anderson Cancer Center ,Incyte Corporation ,China Japan Friendship Hospital ,Lei Qian ,Vice President ,Clinical Development ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,